Stable antibody formulation
US11603407B2 · kind B2 · utility
0Cited by
53References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2018 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | Mar 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human programmed death-1 protein (PD-1). In certain embodiments, the formulations contain, in addition to an anti-PD-1 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.